Medicamen Biotech Limited reported a consolidated net profit of ₹979.64 lakh for the financial year ended March 31, 2026, compared to ₹655.57 lakh in the previous year. The company's total consolidated revenue for FY26 stood at ₹20,088.29 lakh, up from ₹16,879.10 lakh in FY25. The board of directors, meeting on May 27, 2026, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. These results were published in the Financial Express and Jansatta on May 28, 2026, pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

For the quarter ended March 31, 2026, the company recorded a consolidated net profit of ₹444.70 lakh on a total revenue of ₹6,238.18 lakh. In the standalone segment, the net profit for the year was ₹940.87 lakh on revenue of ₹18,195.01 lakh. The earnings per share (EPS) for the consolidated results increased to ₹7.22 for FY26 from ₹5.16 in the previous year.

Dividend Declaration

The board recommended a final dividend of ₹1.00 per equity share of the face value of ₹10 each for the financial year ended March 31, 2026. This dividend is subject to the approval of shareholders at the ensuing Annual General Meeting.

Auditor Appointments

M/s Rai Qimat & Associates, Statutory Auditors, issued an audit report with an unmodified opinion on the financial statements. Additionally, the board approved the appointment of M/s SPB & Co, Cost Accountants, as the Cost Auditor for FY26-27, and M/s Cheena & Associates as the Internal Auditor for the same period. The remuneration for the Cost Auditor is subject to ratification by shareholders.

Medicamen biotech Limited has filed its quarterly compliance certificate with stock exchanges, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company submitted the mandatory documentation for the quarter ended March 31, 2026, confirming compliance with securities dematerialization procedures.

Regulatory Compliance Submission

The company submitted its certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, to both BSE Limited and National Stock Exchange of India Limited on April 15, 2026. Company Secretary Parul Choudhary signed the compliance certificate, which covers securities dematerialization and rematerialization activities during Q4FY26.

Compliance Confirmations

The company provided specific certifications regarding its securities handling procedures during the quarter. The compliance certificate confirms that all securities comprised in the dematerialization certificates have been properly listed on stock exchanges where the company's earlier issued securities were already listed.

Additionally, the company certified that all physical certificates received for dematerialization were mutilated and cancelled after due verification. The depository's name was substituted in the company's records as the registered owner within the mandatory 30-day timeline from receipt.

Registrar Confirmation

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, serves as the company's registrar and share transfer agent. The registrar provided independent confirmation on April 14, 2026, validating the company's compliance with dematerialization procedures.

The registrar confirmed that securities received from depository participants during Q4FY26 were processed according to regulatory requirements, with proper verification and record-keeping procedures followed throughout the quarter.